Navigation Links
Game changer for arthritis and anti-fibrosis drugs
Date:11/11/2012

(SALT LAKE CITY)In a discovery that can fundamentally change how drugs for arthritis, and potentially many other diseases, are made, University of Utah medical researchers have identified a way to treat inflammation while potentially minimizing a serious side effect of current medications: the increased risk for infection.

These findings provide a new roadmap for making powerful anti-inflammatory medicines that will be safer not only for arthritis patients but also for millions of others with inflammation-associated diseases, such as diabetes, traumatic brain injury, and inflammatory bowel disease, according to cardiologist Dean Y. Li, M.D., Ph.D., the U School of Medicine vice dean for research and HA and Edna Benning endowed professor of medicine who led the study. "This can change the way medication is made," he says. "If we can find a way to replace our most powerful drugs for arthritis, we might be able to develop another way to treat inflammation in other diseases that we've been unable to touch because of the danger of suppressing people's immune systems."

The research, funded by the National Institutes of Health (NIH) and published Sunday, Nov. 11, 2012, Nature online, provides the University the opportunity to explore commercializing the technology either through collaboration outside of the state with pharmaceutical companies or within the state via initiatives such as USTAR. The Utah Legislature established USTAR (Utah Science Technology and Research) initiative in 2006 to promote economic growth and high paying jobs through research at the U of U and Utah State University.

"This is just one example of many scientific opportunities for the University and USTAR to work together to benefit not only millions of patients but build medical innovations in Utah," says Li, who's also director of the U of U Molecular Medicine program.

Two Cellular Pathways

When the body undergoes trauma or gets an infection, it responds by releasing cytokinesproteins that enter cells and unleash a three-pronged attack to kill invading bugs, hype up the immune system, and cause inflammation. While inflammation fights infection, it also produces an undesired side effect by weakening blood vessels, which can lead to swelling in the joints, brain or other areas. Scientists long have believed that cytokines use one cellular pathway in their response to infection, meaning that drugs made to block cytokines from causing inflammation also block the immune system and the ability to kill invading bugs.

In a study with mice, Li and his research colleagues upended the one-pathway belief by showing that cytokines use not one but two cellular pathways to battle infection: one to turn on the immune system and kill intruders and a separate one that destroys the architecture of tissues and organs. Identifying the separate pathway for inflammation has vast potential for developing drugs. "We can selectively block inflammation without making the patient immunosuppressed," Li says. "This rewrites the strategy for today's medicines. We focused the work on arthritis given this is a proven market for drugs that reduce damage from inflammation and fibrosis, but we suspect that many other diseases ranging from fibrosis following heart attacks to inflammatory bowel disease may benefit from such an approach."

Li's discovery has dramatic implications for the field of rheumatology, according to Tracy M. Frech, M.D., U of U assistant professor of internal medicine who specializes in rheumatology. "This may lead to more effective treatments for conditions such as lupus, systemic sclerosis, and the spectrum of inflammatory arthritis, without putting patients at risk for infections," she says. "This phenomenal work is a credit to the strong molecular medicine program here at the University of Utah."

Before a new generation of anti-inflammation drugs can be made, researchers must screen for molecules of chemical compounds that can be turned in pharmaceutical-grade drugs, something the University can and should do, according to Li. This can be accomplished either through collaboration with pharmaceutical companies outside of the state or with sources inside Utah, such as the USTAR initiative.


'/>"/>

Contact: Phil Sahm
phil.sahm@hsc.utah.edu
801-581-2517
University of Utah Health Sciences
Source:Eurekalert

Related medicine news :

1. Rheumatoid arthritis patients can get gout too, Mayo Clinic Study finds
2. Researchers identify impact of rheumatoid arthritis and lupus on joint replacement surgery outcomes
3. Hospital-based exercise programs benefit people with osteoarthritis
4. Expensive arthritis treatment no better than steroid therapy
5. Keep Moving to Ease Pain of Knee Arthritis: Review
6. Complementary and alternative therapy improved lives of arthritis patients
7. Elevated Antibody Levels May Predict Rheumatoid Arthritis Risk
8. Newer Rheumatoid Arthritis Drugs Dont Raise Cancer Risk: Study
9. Infections in rheumatoid arthritis patients: Mayo Clinic study finds way to pinpoint risk
10. Introducing decision aids may lower surgery for arthritis
11. Study finds biologic therapies for rheumatoid arthritis not associated with increased cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... Indiana Fiber Network, LLC (IFN), the leading ... as a fiber transport provider. IFN provided Lake City Bank with network services ... , “IFN provides fiber transport to Lake City Bank, which includes protected ...
(Date:5/25/2016)... ... 2016 , ... Today Omega Institute, a leading destination for yoga education in ... opportunities in the growing field of yoga therapy . Yoga therapy adapts ... specific health issues—including injuries, illnesses, and temporary or chronic health conditions. , “Yoga therapy ...
(Date:5/25/2016)... ... May 25, 2016 , ... Afrimesure specializes ... medical and pharmaceutical, to food and HVAC facilities. Their knowledgeable staff also takes ... , For medical applications, Afrimesure offers a variety of MadgeTech systems available for ...
(Date:5/25/2016)... Pittsburgh, Pa. (PRWEB) , ... May 25, 2016 , ... ... announced today that Carol Reichbaum, M.S.L., M.S.P.A., of the University of Pittsburgh Graduate ... , The Fellowship will enable Ms. Reichbaum and 24 other advocates from around the ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State College of Optometry ... work on visual evoked potential and human attention. The article, VEP and Human ... Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 Een app die ... zij collectief patiënten kunnen behandelen, hun kennis kunnen delen ... achter de nieuwe en revolutionaire MDLinking App, ontwikkeld door ... vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... beschikbaar is, wordt op dinsdag 24 mei officieel gepresenteerd ...
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
(Date:5/23/2016)... 23, 2016 Non-invasive diagnostic test ... multiple diseases; ,Technology to be presented at Yissum’s booth, ... Research Development Company of the Hebrew University of Jerusalem ... agreement with Aurum Ventures MKI, the technology investment arm of ... new diagnostic approach for early detection of multiple diseases ...
Breaking Medicine Technology: